Here's Why You Should Add PacBio Stock to Your Portfolio Now

PacBio (PACB) shares have underperformed year-to-date, but the company's Q1 2025 results beat estimates, driven by strong adoption of its Revio and Vega sequencing systems. The company is implementing a restructuring plan to cut $45-50 million in annual operating expenses by the end of 2025, and analysts have narrowed the expected loss per share for 2025. However, longer purchasing cycles, particularly among academic and government institutions, could limit near-term revenue growth.

Analysis

Pacific Biosciences of California (PACB) reported first-quarter 2025 results that surpassed analyst estimates, featuring improved margins and a narrower adjusted operating loss, primarily driven by strong adoption of its Revio and Vega sequencing systems. Despite these operational positives, the company's stock has experienced a significant decline of 43.8% year-to-date, underperforming both its industry and the S&P 500. PacBio is capitalizing on its proprietary HiFi long-read Single-Molecule Real-Time (SMRT) technology and its Onso short-read platform; the global SMRT market alone was valued at $2.74 billion in 2023 and is projected to reach $4.14 billion by 2031, growing at a 5.3% CAGR. Key product momentum includes 97 Revio system shipments in 2024, expanding the installed base to nearly 200 customers, with performance enhanced by the Spark chemistry upgrade which increased yield up to 46%. The newer Vega benchtop system saw 28 units shipped in Q1 2025, with approximately half to new PacBio customers, indicating market expansion. Strategically, PacBio has initiated a company-wide restructuring plan aimed at reducing annualized adjusted operating expenses by $45 million to $50 million by the end of 2025. Analyst sentiment shows some improvement, with the Zacks Consensus Estimate for PacBio's 2025 adjusted loss per share narrowing by 5 cents to 67 cents in the past 30 days, and consensus revenues for 2025 pegged at $155.1 million, representing a 0.7% year-over-year increase, while the company itself projects 19.3% growth for 2025. A critical challenge remains the lengthening of purchasing cycles for its high-cost Revio system, stemming from customer funding uncertainties, tighter capital budgets, specifically NIH funding constraints in the U.S., and broader macroeconomic pressures in the Asia-Pacific region, which pose a risk to near-term revenue growth and may lead to quarterly revenue volatility.

Key Decisions for Investors

• Consider the current valuation following a 43.8% year-to-date stock decline, in light of PacBio's Q1 2025 earnings beat, strong Revio and Vega system adoption, and an ongoing restructuring plan targeting $45-50 million in annual cost savings by end-2025, which collectively suggest potential for recovery.
• Closely monitor the persistent challenge of elongated purchasing cycles driven by customer budget constraints and macroeconomic pressures, as this could impact near-term revenue growth (projected at 0.7% for 2025 by consensus) and introduce volatility, despite positive analyst estimate revisions for loss per share.
• Evaluate PacBio's long-term potential based on its technological differentiation in the expanding SMRT market (projected CAGR 5.3% to $4.14 billion by 2031) against the execution risks associated with high-cost system sales in the current cautious capital spending environment.